Head-to-head · Cost-Efficiency Index
Maves vs Vytora Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesVytora Health
Shoppers who want flat per-dose pricing with a named pharmacy and an optional brand-name fallback, 50 states.
Visit Vytora HealthThe verdict
Maves and Vytora Health tie on the Cost-Efficiency Index at 76/100, so neither wins outright on the numbers. For most shoppers we'd start with Maves (ranked #49, a hair above #51) — Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout. But Vytora Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | Vytora Health |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 76/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | $179/mo (all doses, compounded) |
| Tirzepatide / mo | Not disclosed | $199/mo (all doses, 3-month plan, compounded) |
| Semaglutide / yr (modeled) | $1,068 | $2,148 |
| Tirzepatide / yr (modeled) | — | $2,388 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #49 | #51 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Vytora Health
76/100Where the value is
- Semaglutide pricing is genuinely flat across all doses, not a 'starting at' floor
- 50 states plus DC covered, with per-state video-vs-audio requirements disclosed rather than hidden
- Both compounded and retail brand-name (Mounjaro, Zepbound) options on one platform
The tradeoffs
- The site's own FAQ and pricing page disagree on the 1-month tirzepatide price ($199 vs $249) — get the number confirmed at checkout before assuming either figure
- Brand-name Mounjaro/Zepbound at $1,399/mo is essentially full retail
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.